早期门肺高压可预测肝硬化患者死亡:PORTO-DETECT队列研究
这项多中心纵向观察性队列纳入428例肝硬化伴门脉高压成人,2015至2023年间行右心导管检查,按2022年ESC/ERS新标准分组。中位随访20.0个月,早期门肺高压(mPAP 20.5-24.5 mmHg且PVR>2 Wood单位)3年生存率49.5%,校正后死亡风险仍为正常组的3.5倍(95%CI 1.9-6.3,p<0.01)。
要点
- 2022年新标准定义的早期门肺高压患者死亡风险显著升高。
- 早期门肺高压是独立于肝病严重程度的死亡预测因素。
- 对肝硬化伴门脉高压患者应系统筛查并考虑早期干预。
核心结论
- 应用2022年ESC/ERS的PAH定义可识别出肝硬化合并早期门肺高压患者,其死亡风险明显增加。
- 早期门肺高压是独立于肝病严重程度的死亡预测因素,支持系统筛查和早期靶向干预。
研究设计与样本
- 多中心、纵向、观察性队列研究,纳入428例肝硬化伴门脉高压成人,2015至2023年间行右心导管检查。
- 按血流动力学分为正常、早期门肺高压、经典门肺高压、毛细血管后肺高压和未分类五组。
- 采用多变量Cox回归和竞争风险模型分析全因死亡,肝移植作为竞争事件。
主要发现
- 中位随访20.0个月(IQR 8.0-36.0),正常mPAP、早期门肺高压和经典门肺高压组3年生存率分别为76.7%、49.5%和42.0%。
- 校正年龄、性别、肝功能和门脉高压严重程度后,早期门肺高压死亡风险比为3.5(95%CI 1.9-6.3,p<0.01),经典门肺高压为4.5(95%CI 2.6-7.6,p<0.01)。
- 竞争风险分析中上述关联持续存在,而毛细血管后肺高压和未分类组与正常mPAP队列无差异。
关键数值与推荐
- 早期门肺高压定义为mPAP 20.5-24.5 mmHg且PVR>2 Wood单位(2022年ESC/ERS标准)。
- 早期门肺高压3年生存率49.5%,经典门肺高压42.0%,正常mPAP组76.7%。
- 早期门肺高压校正后HR 3.5(95%CI 1.9-6.3,p<0.01),经典门肺高压HR 4.5(95%CI 2.6-7.6,p<0.01)。
临床怎么用
- 对肝硬化伴门脉高压患者应系统筛查门肺高压,以识别早期阶段。
- 早期门肺高压患者尽管血流动力学改变轻微,仍应密切随访并考虑早期靶向干预。
- 应用2022年ESC/ERS新标准有助于细化风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Portopulmonary hypertension (PoPH) is a severe complication of cirrhosis and portal hypertension. In 2022, a European task force revised the diagnostic criteria for pulmonary arterial hypertension (PAH), defining early stages as a mean pulmonary arterial pressure (mPAP) of 20.5-24.5 mmHg and pulmonary vascular resistance (PVR) >2 Wood units. We evaluated the prognostic value of these revised criteria in patients with cirrhosis. METHODS: In this longitudinal, multicenter, observational cohort, 428 adults with cirrhosis and portal hypertension underwent right-heart catheterization between 2015 and 2023 and were stratified into five groups: normal, early PoPH, classic PoPH, post-capillary pulmonary hypertension, and unclassified profiles. All-cause mortality was analyzed by multivariable Cox regression and competing-risk models, with liver transplantation as an intercurrent event. RESULTS: Over a median follow-up time of 20.0 months (IQR 8.0-36.0), 3-year survival rates were 76.7%, 49.5%, and 42.0% in the normal mPAP, early PoPH, and classic PoPH groups, respectively. After adjustment for age, sex, liver function, and portal hypertension severity, both early PoPH (hazard ratio 3.5; 95% CI 1.9-6.3; p <0.01) and classic PoPH (hazard ratio 4.5; 2.6-7.6; p <0.01) remained independent predictors of mortality vs. normal mPAP; these associations persisted in competing-risk analysis, whereas post-capillary pulmonary hypertension and unclassified groups did not differ from the normal mPAP cohort. CONCLUSION: Applying the 2022 ESC/ERC definitions of PAH identifies a subset of patients with cirrhosis with early-stage PoPH, characterized by mild pulmonary vascular resistance elevation, who nevertheless face a markedly increased risk of death, emphasizing the need for systematic screening and early targeted intervention. IMPACT AND IMPLICATIONS: Portopulmonary hypertension (PoPH) is a severe and often overlooked complication of cirrhosis. Using the updated 2022 ESC/ERS diagnostic criteria, this multicenter study identified a previously unrecognized subgroup of patients with cirrhosis and early-stage PoPH, defined by mildly elevated pulmonary vascular resistance and mean pulmonary artery pressure. Despite their subtle hemodynamic changes, these patients showed significantly reduced survival, independent of liver disease severity. These results highlight the prognostic relevance of early PoPH and suggest that applying the new criteria may help refine risk stratification and guide closer follow-up or earlier consideration of targeted interventions in selected patients.
引用
- Téllez L, Donate J, Guerrero A, et al. Early portopulmonary hypertension predicts mortality in patients with cirrhosis: Insights from the PORTO-DETECT cohort. J Hepatol. 2025. PMID: 41076090. doi:10.1016/j.jhep.2025.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。